Medications & treatment options
GLP-1 Drug Comparisons & Pipeline: Wegovy, Zepbound, Foundayo & Beyond
Patients comparing branded GLP-1s — or evaluating the newer oral and pipeline drugs — need side-by-side trial data, not marketing copy. This cluster collects the head-to-head comparisons (tirzepatide vs semaglutide), the Foundayo / orforglipron deep-dives, and the pipeline drug articles (CagriSema, retatrutide, survodutide, MariTide, ecnoglutide).
103 research articles · newest update November 2026
Start with Tirzepatide vs Semaglutide: A Head-to-Head Look at SURMOUNT and STEP. What the SURMOUNT and STEP trial families actually tell us about which GLP-1 drug produces more weight loss, fewer side effects, and longer-lasting results. The longest read here, at 19 minutes, is Retatrutide and kidney protection: Phase 2 post-hoc evidence and TRANSCEND-CKD. The most recent update (November 2026) went to Foundayo vs Wegovy vs Zepbound: 2026 Head-to-Head.
Within Medications & treatment options, the neighboring topic is Other Weight-Loss Medications & Drugs That Affect Weight (32 articles). After that comes Bariatric Surgery, Endoscopic Procedures & GLP-1s (17 articles). Of the 103 articles filed under this topic, 9 are original data investigations. The full map is on all research topics.
Start here
Tirzepatide vs Semaglutide: A Head-to-Head Look at SURMOUNT and STEP
What the SURMOUNT and STEP trial families actually tell us about which GLP-1 drug produces more weight loss, fewer side effects, and longer-lasting results.
13 min read · Updated July 2026
Foundayo vs Wegovy vs Zepbound: 2026 Head-to-Head
Foundayo (orforglipron), the first non-peptide oral GLP-1 for weight loss, vs Wegovy and Zepbound: 17.2 mg labeled-dose Foundayo 11.1% vs STEP-1 Wegovy 14.9% vs SURMOUNT-1 Zepbound 20.9%, $25 vs $349 vs $449, daily pill vs weekly injection.
13 min read · Updated November 2026
What Is Orforglipron (Foundayo)? Mechanism, Maker & Pronunciation
Orforglipron (Foundayo) is Eli Lilly's once-daily oral GLP-1, the first non-peptide GLP-1 approved for weight loss, cleared by the FDA on April 1, 2026. Being a small molecule is why it can be a pill. How it works, ATTAIN-1 results, and how to pronounce it.
10 min read · Updated July 2026
Foundayo (orforglipron) Approved: The First Non-Peptide Oral GLP-1 Pill for Weight Loss
The FDA approved Foundayo (orforglipron) on April 1, 2026, the first once-daily, non-peptide oral GLP-1 for chronic weight management. It can be taken with or without food, costs $149 a month self-pay at the lowest dose, and averaged 11.1% weight loss in ATTAIN-1.
12 min read · Updated November 2026
Orforglipron (Foundayo) Side Effects: Label Trial Rates
What the FDA Foundayo label and the ATTAIN-1 phase 3 trial actually report for orforglipron side effects — the GI rates, the boxed MTC warning, the pancreatitis and gallbladder signal, and how the oral pill compares to injectable Wegovy and Zepbound.
11 min read · Updated November 2026
Wegovy vs Ozempic vs Zepbound vs Mounjaro: Side-by-Side Comparison & Brand Cheat Sheet (2026)
Wegovy and Ozempic are both semaglutide; Mounjaro and Zepbound are both tirzepatide. This cheat sheet maps each brand to its molecule and indication, with side-by-side efficacy and dosing for Wegovy, Ozempic, Zepbound, Mounjaro, Rybelsus, and Foundayo.
11 min read · Updated November 2026
All 103 articles in this topic
Most recently updated first, after the editor’s picks.
- Tirzepatide vs Semaglutide: A Head-to-Head Look at SURMOUNT and STEP13 min · July 2026
- Foundayo vs Wegovy vs Zepbound: 2026 Head-to-Head13 min · November 2026
- What Is Orforglipron (Foundayo)? Mechanism, Maker & Pronunciation10 min · July 2026
- Foundayo (orforglipron) Approved: The First Non-Peptide Oral GLP-1 Pill for Weight Loss12 min · November 2026
- Orforglipron (Foundayo) Side Effects: Label Trial Rates11 min · November 2026
- Wegovy vs Ozempic vs Zepbound vs Mounjaro: Side-by-Side Comparison & Brand Cheat Sheet (2026)11 min · November 2026
- Can You Take Phentermine With a GLP-1? The Combination Therapy Evidence and the Safety Concerns11 min · August 2026
- Beyond Wegovy and Zepbound: Three Pipeline GLP-1 Drugs to Watch11 min · August 2026
- CagriSema REDEFINE: What Novo Nordisk's Amylin Combination Actually Showed13 min · November 2026
- Retatrutide: What We Know About Lilly's Triple Agonist as TRIUMPH-4 Reads Out13 min · October 2026
- Berberine vs GLP-1s: What the Evidence Actually Shows About "Nature's Ozempic"12 min · November 2026
- What STEP-TEENS Showed: Semaglutide for Adolescents with Obesity12 min · August 2026
- Ozempic Without Diabetes: Off-Label Use for Weight Loss Evidence Review12 min · November 2026
- Wegovy for Teenagers: Patient + Parent Guide (Evidence Review)13 min · November 2026
- Ozempic + Metformin: FDA Label, SUSTAIN-3/4 Evidence & Combination Therapy Review14 min · August 2026
- ATTAIN-MAINTAIN: Can a Pill Hold Weight Loss After Injections?7 min
- Do GLP-1s Cost More Muscle Than Dieting? What the Comparisons Show7 min
- Tirzepatide vs GLP-1s for Heart Outcomes: What Meta-Analyses Show9 min
- What Is Ecnoglutide? The cAMP-Biased GLP-1 and Its Trial Data8 min
- Zenagamtide Pill vs Shot: What the Phase 2 Lancet Reports Found7 min
- ZUPREME-1: Petrelintide Phase 2 Weight Loss Results8 min
- Mazdutide vs Dulaglutide in Type 2 Diabetes: The Nature Trials8 min
- Semaglutide vs Tirzepatide: Which Has Higher NAION Risk?8 min
- GLORY-2: How Much Weight Did Mazdutide 9 mg Produce?7 min
- Orforglipron and the Heart: The Lancet Cardiovascular Safety Trial8 min
- Survodutide for Fatty Liver: What the Phase 3 Nature Medicine Trial Shows8 min
- 16:8 vs 5:2 Fasting: Which Works Better for Weight Loss?8 min
- SYNCHRONIZE-1: Survodutide Phase 3 Obesity Results Explained8 min
- Wegovy HD 7.2 mg vs 2.4 mg: Who Benefits From the Higher Dose?7 min
- ACHIEVE: Oral Orforglipron in Type 2 Diabetes (2026)13 min · November 2026
- Amycretin (Zenagamtide): Novo's Next-Gen Dual Amylin/GLP-1 Drug11 min · November 2026
- ATTAIN: Oral Orforglipron for Obesity (2026)13 min · November 2026
- Bimagrumab: The Muscle-Preserving Weight-Loss Antibody — Evidence Review9 min · November 2026
- Foundayo (Orforglipron) Side Effects: Comprehensive Evidence Review14 min · November 2026
- GLP-1 Pills (2026): Rybelsus, Foundayo & the New Wegovy Tablet — Side-by-Side Comparison of Every Oral GLP-113 min · November 2026
- GLP-1 Pipeline Tracker: Every Next-Gen Weight-Loss Drug in Development (2026)7 min · November 2026
- Is Orforglipron Safe for the Liver? The Pooled Phase 3 Data8 min
- Is Wegovy the Same as Ozempic? Is Zepbound the Same as Mounjaro? Complete GLP-1 Disambiguation FAQ (2026)13 min · November 2026
- Is Wegovy the Same as Semaglutide? Brand vs Generic Disambiguation7 min · November 2026
- Mounjaro Alternatives (2026): T2D-Approved GLP-1s, Tirzepatide Cousins (Zepbound), and Off-Label vs On-Label Decisions13 min · November 2026
- Mounjaro vs Trulicity: Glycemic Control and Switching Evidence9 min · November 2026
- Orforglipron vs Rybelsus: How the Two Oral GLP-1 Pills Compare (2026)9 min · November 2026
- Ozempic Alternatives (2026): FDA-Approved GLP-1s, Cheaper Semaglutide & Non-GLP-1 Options9 min · November 2026
- Phentermine vs Ozempic: Different Drug Classes, Different FDA Approvals14 min · November 2026
- REDEFINE: The Full CagriSema Trial Program (2026)13 min · November 2026
- Retatrutide Approval & Access Timeline: TRIUMPH Results, 2027 FDA Filing, No Compounding12 min · November 2026
- Retatrutide Before and After: What TRIUMPH-1 Actually Showed12 min · November 2026
- Retatrutide Dosage: TRIUMPH-1 Escalation Ladder + Clinical Evidence12 min · November 2026
- Retatrutide Side Effects: Comprehensive Phase 3 Evidence Review15 min · November 2026
- Retatrutide TRIUMPH Phase 3: Latest Pipeline Update11 min · November 2026
- Retatrutide vs Foundayo (orforglipron) — TRIUMPH-1 vs ATTAIN-1 cross-trial evidence12 min · November 2026
- Retatrutide vs Ozempic: T2D Phase 2 Cross-Trial Evidence (vs SUSTAIN-7)12 min · November 2026
- Retatrutide vs tirzepatide — TRIUMPH-1 vs SURMOUNT-1 head-to-head evidence11 min · November 2026
- Retatrutide vs Wegovy: cross-trial weight-loss + safety evidence (2026)12 min · November 2026
- Rybelsus Alternatives: When Oral Semaglutide Isn't Working — Switching to Foundayo, Wegovy, or Compounded (2026)13 min · November 2026
- Rybelsus Pill vs Ozempic Injection: Same Drug, Different Result?12 min · November 2026
- STEP UP: Semaglutide 7.2 mg High-Dose Trial (2026)13 min · November 2026
- SURMOUNT-5: Tirzepatide vs Semaglutide Head-to-Head (2026)13 min · November 2026
- The Incretin Effect Explained: GLP-1, GIP & Why It Matters11 min · November 2026
- Tirzepatide Body Composition: SURMOUNT-1 & SURPASS-3 Imaging13 min · November 2026
- Tirzepatide vs Retatrutide: GIP/GLP-1 vs Triple Agonist Evidence11 min · November 2026
- Trulicity Alternatives: Dulaglutide Decision Guide (Mounjaro, Ozempic, Generics)14 min · November 2026
- Trulicity vs Ozempic vs Mounjaro for T2D: Head-to-Head Evidence11 min · November 2026
- VK2735 (Viking Therapeutics): GIP/GLP-1 Dual Agonist Weight-Loss Evidence9 min · November 2026
- Wegovy Alternatives (2026): Zepbound, Foundayo, Saxenda & Compounded Semaglutide12 min · November 2026
- Wegovy Pill vs Wegovy Injection: How Close Are the Results?7 min
- Wegovy vs Mounjaro: Different Molecules, Different Indications — How to Choose (2026)9 min · November 2026
- What Is Mazdutide? The Obesity Drug Approved in China, Not the US6 min · November 2026
- What Is the Best GLP-1 for Weight Loss? Ranked by FDA Evidence (2026)13 min · November 2026
- The Next GLP-1 Pills: Elecoglipron, Aleniglipron and Other Oral Drugs in Trials8 min · October 2026
- What Is Eloralintide? Lilly's Amylin Weight-Loss Drug Explained7 min · October 2026
- 2026 Obesity Medication Guidelines: ACP, Obesity Societies and VA/DoD Compared8 min · October 2026
- Cagrilintide: The Amylin Analogue Behind CagriSema — What the Evidence Shows8 min · October 2026
- Foundayo vs Wegovy: Head-to-Head Evidence Comparison14 min · October 2026
- GLP-1 Medication List 2026: Every FDA-Approved & Investigational GLP-1 Drug14 min · October 2026
- GLP-1 Trial Results Q3 2026: Retatrutide TRIUMPH, Survodutide & Orforglipron ACHIEVE-414 min · October 2026
- Mazdutide (IBI362): GLP-1/Glucagon Dual Agonist Weight-Loss Evidence9 min · October 2026
- Newest GLP-1 Drugs (2026): Foundayo, Recently Approved & Pipeline Launches in Order13 min · October 2026
- Pemvidutide (Altimmune): GLP-1/Glucagon Dual Agonist Weight-Loss Evidence9 min · October 2026
- Retatrutide and kidney protection: Phase 2 post-hoc evidence and TRANSCEND-CKD19 min · October 2026
- Retatrutide for MASH and MASLD: What the Phase 2a Liver-Fat Data Show13 min · October 2026
- Retatrutide for type 2 diabetes: TRIUMPH-2 Phase 3 results and Phase 2 evidence18 min · October 2026
- Weight Loss Injections Guide 2026 — Every FDA-Approved Option, Effectiveness, Cost, Safety18 min · October 2026
- What is GIP? GIP Receptor Explained (And Why Mounjaro/Zepbound Activate It Alongside GLP-1)13 min · October 2026
- The Wegovy Pill (Oral Semaglutide 25 mg): Dosing, Results and Cost11 min · September 2026
- What Is Cagrilintide? The Amylin Analog Behind CagriSema6 min · August 2026
- What Is GLP-3? There Is No Such Hormone — Here's What People Mean6 min · August 2026
- What Is Petrelintide? Zealand's Long-Acting Amylin Analog5 min · August 2026
- What Is Survodutide? The Glucagon/GLP-1 Dual Agonist in Phase 35 min · August 2026
- Oral Tirzepatide: Does a Pill Version Exist, and Does It Work?8 min · August 2026
- Danuglipron: Why Pfizer Discontinued Its Oral GLP-1 Pill9 min · August 2026
- Diabetes Weight Loss Drug — Which Is Which? Untangling Ozempic, Mounjaro, Wegovy, Zepbound, Foundayo (2026)7 min · August 2026
- GLP-1 Weight-Loss Trial Results: The Complete Database (STEP, SURMOUNT & Every Major Trial)10 min · August 2026
- Mounjaro vs Zepbound: Should You Switch? The Evidence11 min · August 2026
- Oral vs Injectable GLP-1: Cost, Effectiveness & How to Choose (2026)9 min · August 2026
- Semaglutide vs Tirzepatide: How Their Side Effects Compare (2026)9 min · August 2026
- What Is GLP-1? How the Hormone & the Medications Work for Weight Loss (2026)9 min · August 2026
- Zepbound Generic / Tirzepatide Biosimilar: When Will It Be Available? (2026 Status)7 min · August 2026
- Zepbound vs Wegovy Side Effects: Head-to-Head Comparison from the FDA Labels (2026)8 min · August 2026
- GLP-1 Generics (2026): When Will Wegovy, Ozempic, Mounjaro & Zepbound Go Generic?12 min · July 2026
- Mounjaro vs Zepbound: Same Drug, Different Brands — Why the Distinction Matters for Coverage and Cost18 min · July 2026
- Wegovy vs Ozempic: Same Molecule, Different FDA Approvals — Evidence Review15 min · July 2026
- Mounjaro vs Zepbound: Same Drug, Different Brand Names — Complete Side-by-Side Comparison (2026)10 min · July 2026